Efficacy of latanoprost additive therapy on uncontrolled glaucoma

Ophthalmologica

Volumn 216, Issue 6, 2002, Pages 443-448

  Bayer, Atilla ^a   Tas, Ahmet ^a   Sobaci, Gungor ^a   Henderer, Jeffrey D ^b  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b WILLS EYE HOSPITAL   (United States)

Author keywords

Adjunctive treatment; Latanoprost; Uncontrolled glaucoma

Indexed keywords

ANTIGLAUCOMA AGENT; APRACLONIDINE; BETAXOLOL; CARTEOLOL; DORZOLAMIDE; LATANOPROST; PILOCARPINE; TIMOLOL MALEATE;

ADULT; AGED; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LENS IMPLANTATION; MALE; OCULAR ALLERGY; PROGNOSIS; TRABECULECTOMY; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; FEMALE; FOLLOW-UP STUDIES; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PROSTAGLANDINS F, SYNTHETIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036962902     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000067545     Document Type: Article

References (21)

1. Camras CB, Bito LZ: Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2-alpha. Curr Eye Res 1981;1:205-209.
2. Nilsson SEF, Samuelsson M, Bill A, Stjernschantz J: Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2-alpha-1-isopropyl ester in the cynomolgus monkey. Exp Eye Res 1989;48:707-716.
3. Resul B, Stjernschantz J, No K, et al: Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agents. J Med Chem 1993;36:243-248.
4. Nagasubramanian S, Sheth GP, Hitchings PA, Stjernschantz J: Intraocular pressure-reducing effect of PhxA41 in ocular hypertension: Comparison of dose regimen. Ophthalmology 1993;100:1305-1311.
5. Friström B, Nilsson SEG: Interaction of PhxA41, a new prostaglandin analogue, with pilocarpine. Arch Ophthalmol 1993;111:662-665.
6. Hotehama Y, Mishima HK, Kitazawa Y, Masuda K: Ocular hypotensive effect of PhxA41 in patients with ocular hypertension or primary open-angle glaucoma. Jpn J Ophthalmol 1993;37:270-274.
7. Susanna R, Giamphani J, Borges AS, Vessani RM, Jardao MLS: A double-masked, randomized clinical trial comparing latanoprost with unoprostone in patients with open-angle glaucoma or ocular hypertension. Ophthalmology 2001;108:259-263.
8. Polo V, Larossa M, Gomez L, Pablo L, Honrubia FM: Latanoprost versus combined therapy with timolol plus dorzolamide: IOP-lowering effect in open-angle glaucoma. Acta Ophthalmol Scand 2001;79:6-9.
9. Rulo AH, Greve EL, Geijssen HC, Hoyng PFJ: Reduction of intraocular pressure with treatment of latanoprost once daily in patients with normal-pressure glaucoma. Ophthalmology 1996;103:1276-1282.
10. Simmons ST, Samuelson TW: Comparison of brimonidine with latanoprost in the adjunctive treatment of glaucoma. Clin Ther 2000;22:388-399.
11. Vetrugno M, Maino A, Quaranta GM, Cardia L: A randomized, comparative open-label study on the efficacy of latanoprost and timolol in steroid induced ocular hypertension after photorefractive keratectomy. Eur J Ophthalmol 2000;10:205-211.
12. Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE: A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma. Ophthalmology 1999;106:550-555.
13. Ziai N, Dolan JW, Kacere RD, Brubaker RF: The effects on aqueous dynamics of PhxA41, a new prostaglandin F2a analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351-1358.
14. Hoyng PF, Rulo A, Greve E, et al: The additive intraocular pressure-lowering effect of latanoprost in combined therapy with other ocular hypotensive agents. Surv Ophthalmol 1997;41(suppl 2):S93-S98.
15. Shin DH, McCracken MS, Bendel RE, et al: The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy. Ophthalmology 1999;106:386-390.
16. DesMarchais B, Candal E, Weitzman M, Shields MB: Effect of latanoprost as adjunctive therapy. Can J Ophthalmol 2000;35:214-217.
17. Patelska B, Greenfield DS, Liebmann JM, Wand M, Kushnick H, Ritch R: Latanoprost for uncontrolled glaucoma in a compassionate case protocol. Am J Ophthalmol 1997;124:279-286.
18. Alm A, Widengård I: Latanoprost: Experience of 2-year treatment in Scandinavia. Acta Ophthalmol Scand 2000;78:71-76.
19. Alm A, Stjernschantz J, Scandinavian Latanoprost Study Group: Effects on intraocular pressure and side effect of 0.005% latanoprost applied once daily, evening or morning: A comparison with timolol. Ophthalmology 1995;102:1743-1752.
20. Watson P, Stjernschantz J, Latanoprost Study Group: A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 1996;103:126-137.
21. Camras CB, United States Latanoprost Study Group: Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: A six-month, masked, multicenter trial in the United States. Ophthalmology 1996;103:138-147.